



Adding Smiles To Life

To,  
National Stock Exchange of India Ltd.  
Exchange Plaza, C 1, Block G,  
Bandra - Kurla Complex,  
Bandra (E),  
Mumbai - 400 051.

**Company Symbol: QMSMEDI**

**ISIN: INEOFMW01018**

**Sub: Press Release – Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023**

Pursuant to Regulation 30 of the SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, enclosed herewith the copy of the Press Release with regard to the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023.

A copy of the press release is also uploaded on the Company's website.

Kindly take the same on your records and oblige.

Thanking you,

**Yours truly,**

**FOR QMS MEDICAL ALLIED SERVICES LIMITED**

**TORAL BHADRA  
COMPANY SECRETARY AND COMPLIANCE OFFICER  
MEMBERSHIP NO.: A56927  
DATE: NOVEMBER 15, 2023  
PLACE: MUMBAI**

---

**QMS Medical Allied Services Ltd.**

📍 1A-1B / 2A-2B, Navkala Bharati Building, Plot No. 16, Prabhat Colony, Road No. 3, Santacruz (East), Mumbai - 400 055.

☎ +91-022 - 6288 1111 🌐 [www.qmsmas.com](http://www.qmsmas.com)

CIN: U33309MH2017PLC299748; Email Id: [mm@qmsmas.com](mailto:mm@qmsmas.com)



## QMS Boasts a Stunning 118% Profit Surge in H1 FY24!

Mumbai 13<sup>th</sup> November, 2023 – QMS Medical Allied Services Limited, is engaged in the marketing and distribution of a wide range of medical products as well as medical education services, has announced its Unaudited Financial Results for H1 & Q2 FY24.

### Key Financials at a Glance:

#### H1 FY24:

Particulars (₹ crore)	H1 FY24	H1 FY23	YoY Change
Total Income	54.80	52.32	↑ 4.73%
EBITDA	9.75	4.92	↑ 98.36%
EBITDA Margin (%)	17.79	9.39	↑ 840 Bps
PAT	5.02	2.30	↑ 117.89%
PAT Margin (%)	9.16	4.40	↑ 476 Bps
EPS (₹)	2.81	1.53	↑ 83.66%

#### Q2 FY24:

Particulars (₹ crore)	Q2 FY24	Q2 FY23	YoY Change
Total Income	28.76	27.64	↑ 4.04%
EBITDA	5.01	3.06	↑ 63.49%
EBITDA Margin (%)	17.42	11.09	↑ 633 Bps
PAT	2.56	1.64	↑ 56.49%
PAT Margin (%)	8.90	5.92	↑ 298 Bps
EPS (₹)	1.43	1.09	↑ 31.19%

Commenting on the performance, **Mr. Mahesh Makhija, Chairman and Managing Director, mentioned,** “In assessing our first-half performance, I am pleased to report that we have embarked on a positive trajectory. The investments and efforts dedicated to our business verticals, such as Camps and Q devices in preceding financial years, are now manifesting in tangible results, contributing to our notable growth. This achievement is a testament to our persistent commitment.

Our proactive pursuit of quality inorganic growth opportunities is evidenced by the recent acquisitions of Saarathi Healthcare Private Limited and Prometheus Healthcare Private Limited. These strategic moves are anticipated to not only fortify our current standing but also provide a substantial boost for the remainder of FY24 and beyond.

Looking ahead, I am optimistic about the future, buoyed by our current successes

and strategic maneuvers. We are confident our continued success and the sustained growth that lies ahead.”

**About QMS Medical Allied Services Limited:**

Incorporated in 2017, QMS Medical Allied Services Limited is a leading medical and healthcare entity in India, specializing in the marketing and distribution of essential devices and accessories. With a focus on quality and affordability, the company offers a wide range of devices under the "Q-Devices" brand, including glucometers, pulse oximeters, thermometers, monitors, anatomical sets, neurology kits, and orthopaedic aids.

The company also excels in medical consumables like disinfectants, filters, and wound care products. Its distribution network ensures widespread accessibility, while strategic marketing initiatives enhance brand recognition and growth. The company is also at the forefront of medical education, offering evidence-based programs and CME opportunities endorsed by the EACME. Additionally, it hosts preventive and diagnostic camps, promoting healthcare practitioners' empowerment and superior therapy outcomes nationwide.

In FY23, the Company has reported Total Revenue of ₹ 104.04Cr with EBITDA of ₹ 12.07Cr & Net Profit of ₹ 6.38Cr.

**Disclaimer:**

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

**For further information please contact corporate communication advisor:**



Sunil Mudgal – Director  
Kirin Advisors Private Limited  
[sunil@kirinadvisors.com](mailto:sunil@kirinadvisors.com)  
M – 9869275849